Understand the source comparison
Best Follistatin-344 Dosage for Myostatin Inhibition 2026: Research Model Comparison
100mcg daily (single dose) 35–45% 12–18% increase in lean mass Minimal. Activin binding <10% Entry-level protocol for first-time researchers; myostatin suppression is measurable but submaximal; safe margin for long-term studies 150mcg twice daily (300mcg total
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 100mcg daily (single dose)
- 35–45%
- 12–18% increase in lean mass
- Minimal. Activin binding <10%
- Entry-level protocol for first-time researchers; myostatin suppression is measurable but submaximal; safe margin for long-term studies
- 150mcg twice daily (300mcg total)
- 65–70%
- 25–35% increase in lean mass
- Low. Activin binding 10–15%
- Optimal for most research applications; sustained myostatin blockade without plateau; twice-daily dosing maintains consistent plasma levels
- 300mcg single daily dose
- 60–68%
- 22–30% increase in lean mass
- Moderate. Activin binding 15–20% during peak
- Equivalent myostatin suppression to split-dose 300mcg but with higher trough periods; less consistent blockade; may elevate FSH/LH suppression risk
- 600mcg daily
- 70–75%
- 28–32% increase in lean mass
- High. Activin binding 30–40%
- Marginal additional myostatin suppression vs 300mcg; disproportionate off-target risk; not recommended unless specific research question requires saturation dosing
- The 150mcg twice-daily protocol consistently demonstrates the most favourable risk-to-benefit profile across preclinical models. Maximal myostatin inhibition with minimal off-target activin or BMP interference. Higher doses add cost and risk without meaningful efficacy gains.